Drug intelligence / Profile preview

clefamide

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Clefamide is a small molecule antiprotozoal agent of the diphenylether class that was used primarily in the 1960s for the treatment and chemoprophylaxis of amoebiasis, specifically infections caused by *Entamoeba histolytica*. It acts as a luminal amoebicide, targeting protozoa within the intestinal lumen. Clefamide is no longer in clinical use and there is no evidence for its continued application after its initial period of use[1][3][7]. Its mechanism of action has not been fully elucidated but it was classified among agents effective against amoebozoa[1][3].

Brand names: Mebinol
Other names: clefamideMebinol

Beyond the preview

Go deeper on clefamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clefamide.

Explore the full profile